Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
What's Your Reaction?
